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Altered microRnA and target gene 
expression related to tetralogy of 
fallot
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MicroRnAs (miRnAs) play an important role in guiding development and maintaining function of the 
human heart. Dysregulation of miRnAs has been linked to various congenital heart diseases including 
Tetralogy of Fallot (TOF), which represents the most common cyanotic heart malformation in humans. 
Several studies have identified dysregulated miRNAs in right ventricular (RV) tissues of TOF patients. In 
this study, we profiled genome-wide the whole transcriptome and analyzed the relationship of miRNAs 
and mRNAs of RV tissues of a homogeneous group of 22 non-syndromic TOF patients. Observed profiles 
were compared to profiles obtained from right and left ventricular tissue of normal hearts. To reduce 
the commonly observed large list of predicted target genes of dysregulated miRNAs, we applied a 
stringent target prediction pipeline integrating probabilities for miRNA-mRNA interaction. The final list 
of disease-related miRNA-mRNA pairs comprises novel as well as known miRNAs including miR-1 and 
miR-133, which are essential to cardiac development and function by regulating KCNJ2, FBN2, SLC38A3 
and TNNI1. Overall, our study provides additional insights into post-transcriptional gene regulation of 
malformed hearts of tof patients.
Over the last century, cardiovascular diseases have slowly overtaken infectious diseases as the leading cause of 
death worldwide. Among various subdivisions, congenital heart diseases (CHDs) feature prominently and con-
tribute appreciably to the mortality rates1. The symptoms vary from life-threatening at one extreme to somewhat 
benign. One severe malformation is Tetralogy of Fallot (TOF). This heart defect is the most common cyanotic one 
with a prevalence of ~0.3 per 1.000 live births, accounting for 7–10% of all CHDs2,3. TOF is characterized by four 
structural abnormalities, namely a narrowing of the right outflow tract (pulmonary stenosis), a ventricular septal 
defect (VSD), a displacement of the aorta to the right side over the VSD (an overriding aorta) and a hypertrophy 
of the right ventricle3,4. Like the majority of CHDs, TOF is most probably caused by an interplay of multiple subtle 
genetic, structural genomic or epigenetic alterations with environmental stimuli5–9. Moreover, etiologies of CHDs 
also include the disruption of developmentally transcriptional regulation, which requires precise spatiotemporal 
control of gene expression8. Here, post-transcriptional regulation by microRNAs (miRNAs) has emerged as an 
important regulator in development and maintaining function of the human heart8,10.
MicroRNAs are small, non-coding RNAs that non-precisely complementary bind to the 3′ untranslated 
regions of target mRNA, which results in translational repression or mRNA degradation11. Studies have been per-
formed on tissue-specific and circulating miRNAs as novel diagnostic and prognostic biomarkers12–14. Recently, 
altered expression levels of circulating miRNAs were found in blood of TOF patients after surgical repair being 
mainly surgical related. These miRNAs differ compared to those seen in the right ventricle (RV) of the patients15 
and show limited correlation with cardiac functional indices assessed by echocardiography16. Studies of cardiac 
tissue of TOF range from single candidate approaches to microarray studies17–21 up to whole small RNA tran-
scriptome analysis using high-throughput sequencing22. Overall, these studies show a broad range of altered 
miRNAs in TOF with heterogeneous results between them.
Here, we profiled genome-wide the whole transcriptome in cardiac tissues. We analyzed the relationship of 
miRNAs and mRNAs in RV tissue of a homogeneous group of non-syndromic TOF patients compared to normal 
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right and left heart controls. To narrow down the large list of putative functional target genes of differentially 
expressed miRNAs, the expression is correlated to mRNA expression profiles of cardiac tissue from the same 
group of patients and controls. By this, we add a novel layer of data as this comparison was so far limited.
Results
Quality, mapping and annotation of sequencing data. Small RNA sequencing of RV tissue of 22 iso-
lated TOF patients (TOF-rv) as well as tissue from RV and LV of four normal hearts (NH-rv and NH-lv, respec-
tively) serving as controls (Supplementary Fig. S1) revealed on average 15 million reads per sample. Sequencing 
data suggest a good sequencing quality for all samples, with on average 4.1 million unique read sequences per 
samples (Table 1). On average, 12.8 million (86%) of the input reads could be mapped to human reference genome 
(Table 1). The read length distribution of mapped reads is representative for small RNA sequences, meaning 
18–36 nucleotides (nt) (Supplementary Fig. S2A). Using annotations from miRBase, the majority of the mapped 
reads could be assigned to known mature miRNA sequences (Fig. 1A left), comprising a read length distribution 
between 18 and 25 nt with a peak near the average mapped read length of 22 nt (75.2% of the mapped reads), 
which is representative for mature sequences (Supplementary Fig. S2B). After annotation of miRNAs, the remain-
ing mapped reads were assigned to other known non-coding RNAs, mRNA sequences and genomic repeats. The 
most abundant classes of non-coding RNAs except miRNAs are rRNAs and tRNAs (Fig. 1A right). In general, the 
amount of non-coding RNAs except miRNAs is small (~1.8%), which indicates an accurate library preparation 
and low contamination over all small RNA-seq libraries. The relatively high number of reads assigned to mRNAs 
and genomic repeats could be attributed to ambiguously mapped reads, unannotated microRNAs or short mRNA 
degradation products.
Sample Tissue Reads
Unique read 
sequences GC (in %)
Sequence duplication 
levels (in %) Mapped reads
NH-01 LV 14,111,358 2,865,658 30 70 12,891,425 91%
NH-03 LV 12,230,279 3,343,404 43 47 9,058,367 74%
NH-05 LV 13,936,063 3,260,509 31 60 10,387,224 75%
NH-07 LV 14,794,093 3,805,985 31 63 12,490,569 84%
mean in NH-lv 13,767,948 3,318,889 34 60 11,206,896 81%
NH-02 RV 16,270,049 5,396,081 30 55 14,358,788 88%
NH-04 RV 12,940,172 2,303,102 31 75 11,688,828 90%
NH-06 RV 14,475,968 3,911,569 29 65 13,181,979 91%
NH-08 RV 14,890,970 3,720,101 30 67 13,637,109 92%
mean in NH-rv 14,644,290 3,832,713 30 66 13,216,676 90%
TOF-01 RV 15,618,489 6,185,939 35 49 14,155,706 91%
TOF-02 RV 14,247,548 3,616,342 43 65 11,871,100 83%
TOF-03 RV 16,154,319 5,027,091 35 55 13,947,241 86%
TOF-04 RV 13,530,942 3,037,292 39 67 12,062,813 89%
TOF-05 RV 13,178,983 2,458,431 39 75 11,943,094 91%
TOF-06 RV 15,681,483 4,165,561 43 59 13,239,917 84%
TOF-07 RV 14,459,386 2,717,782 40 67 12,322,079 85%
TOF-08 RV 14,893,149 4,646,465 40 59 12,967,004 87%
TOF-09 RV 16,226,821 6,988,240 38 33 12,957,736 80%
TOF-10 RV 15,467,857 3,978,431 43 58 12,947,678 84%
TOF-11 RV 14,989,342 5,846,310 44 56 12,597,864 84%
TOF-12 RV 14,684,351 5,124,711 44 58 12,110,460 82%
TOF-13 RV 15,412,115 3,826,079 35 60 13,811,681 90%
TOF-14 RV 14,722,727 3,724,013 35 56 12,538,399 85%
TOF-15 RV 14,982,308 3,698,674 34 57 13,423,968 90%
TOF-16 RV 16,914,098 4,066,034 41 58 13,911,659 82%
TOF-17 RV 15,860,118 3,046,123 42 68 13,550,609 85%
TOF-18 RV 16,542,142 5,849,400 40 50 14,442,540 87%
TOF-19 RV 14,560,854 3,479,567 41 61 12,096,704 83%
TOF-20 RV 17,891,078 5,110,475 42 55 14,372,964 80%
TOF-21 RV 14,033,794 2,975,214 41 68 12,290,647 88%
TOF-22 RV 16,296,019 3,863,386 42 63 13,766,977 84%
mean in TOF-rv 15,288,542 4,246,889 40 59 13,060,402 86%
Table 1. Small RNA sequencing read statistics and mapping to human reference genome (hg19). LV: left 
ventricle; NH: normal heart; RV: right ventricle; TOF: Tetralogy of Fallot.
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Quantification of miRNAs. Overall, a higher proportion of reads associated to miRNAs was found in TOF 
patients compared to controls (Fig. 1A). In total, 657 expressed miRNAs (Tag Count Comparison [TCC] > 1) 
were found in TOF-rv or normal heart controls. After miRNA quantification and read count normalization, the 
samples were assessed based on multidimensional scaling (Fig. 1B,C). We identified the samples NH-03 (left 
ventricle) and TOF-09 (right ventricle) as clearly separated from the others in the first and second dimension 
(Fig. 1B), respectively, which may be related to the sequencing results. (Table 1). Thus, both samples were classi-
fied as outliers and were subsequently removed from further analysis.
Differential expression analysis. To define differential expression between TOF patients and con-
trols, 21 TOF samples and four normal heart samples from the right ventricle were compared. The analy-
sis revealed 172 significantly differentially expressed miRNAs (adjusted p-value < 0.05 and fold change ≥ 1.5; 
Supplementary Table S1). Most of these miRNAs were up-regulated in TOF (in total 111) including several 
heart- and muscle-relevant miRNAs (e.g., miR-206, miR-29a-5p, miR-378, and miR-127). Approximately one 
third of the miRNAs were down-regulated in TOF (in total 61) including important miRNAs such as miR-1, 
miR-133b, miR-19a/b-3p, and miR-29c (Fig. 2A). We further checked possible expression differences of iden-
tified miRNAs between patients with and without dilated right ventricle or muscular intra-ventricular septum 
defect. However, we found overall no obvious or significant expression difference based on hierarchical clustering 
as well as mean expression correlations (Supplementary Fig. S3). This holds true for other clinical parameters, 
including for example O2 saturation, systolic pressure in RV and pulmonary valve morphology, where one can 
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Figure 1. Annotation of mapped reads and multi-dimensional scaling of normalized read counts. (A) 
Overview of annotated mapped read sequences of miRNAs, mRNAs, repeats, unknown origin and other small 
RNAs in left ventricle (NH-lv) as well as right ventricle of normal hearts (NH-rv) and TOF patients (TOF-rv). 
Multi-dimensional scaling before (B) and after removal of outliers (NH-03 and TOF-09) as well as NH-lv 
samples in general. (C) Scaling based on TCC normalized miRNA read counts. LogFC: log fold change; lv: left 
ventricle; NH: normal heart; rv: right ventricle; TOF: Tetralogy of Fallot.
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identify sub-classes based on phenotype data (Supplementary Fig. S1). In general, the differentially expressed 
miRNAs are randomly distributed over all chromosomes of the human genome and no clusters could be identi-
fied (Fig. 2B). Moreover, the majority (in total 122) overlap with protein-coding genes (Fig. 2C). Most of the miR-
NAs are located on the same strand of both protein-coding or non-protein-coding host genes. However, miRNAs 
located on non-protein coding genes were nearly exclusively located in exonic regions of gene transcripts whereas 
miRNAs on protein-coding genes were mostly located in exonic/intronic regions (Fig. 2C).
For the 172 significantly differentially expressed miRNAs, we searched for possible age-related candidates 
with a continuous increase or decrease of the normalized reads counts from infant TOF hearts to young and 
mid-age adult normal hearts (i.e., TOFs 0–3 y < NH-04 18 y < NH-06 20 y < NH-02 25 y < NH-08 37 y). Among 
the 111 up-regulated miRNAs in TOF, we only found three miRNAs (miR-3124-5p, miR-3127-5p and miR-
618), which harbor decreased reads counts from infant TOF hearts to the mid-age adult heart of NH-08. For 
the 61 down-regulated miRNAs, there are five miRNAs (let-7a-3p, miR-126-3p, miR-140-5p, miR-21-5p and 
miR-98-5p) with continuous increased read counts from infant TOF hearts to the mid-age adult normal heart. 
Whether differential expression of these miRNAs between TOF and normal heart (only 5 out of 172) is age- 
or disease-related cannot be clearly determined and therefore, we did not exclude these miRNAs from further 
analysis.
Differential expression analysis between right and left ventricles of normal hearts revealed exclusively miR-
223-3p being down-regulated in NH-rv compared to NH-lv (mean TCC read count of 64 in NH-rv and mean 
TCC read count of 329 in NH-lv; adjusted p-value of 0.025). Interestingly, miR-223-3p is also down-regulated 
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Figure 2. Significantly differentially expressed miRNAs in TOF-rv compared to NH-rv. (A) Heatmap based 
on 172 differentially expressed miRNAs in right ventricular tissue of TOF patients and normal heart controls. 
All read counts are based on TCC normalized expression values. The heatmap was produced using McQuitty’s 
similarity cluster analysis with a correlation metric distance. The data were dual scaled to the limits -3,3 
before clustering. (B) Genomic locations of miRNAs over all human chromosomes. (C) Locations of miRNAs 
from where they are transcribed, distinguishing between coding and non-coding regions; intronic, exonic or 
intergenic regions; and strand position.
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in the TOF-rv compared to NH-rv, which is characterized by a hypertrophic cardiac RV mass and increased 
ventricular pressure that is in line with the comparison of NH-rv and NH-lv. This miRNA regulates the Glucose 
Transporter 4 (Glut4) protein expression and cardiomyocyte glucose metabolism23. Approximately 25% of the 
differentially expressed miRNAs (43 out of 172) overlaps with results from other studies based on right ven-
tricular tissue of TOF patients versus normal hearts, with only one miRNA altered in all studies, namely miR-
222-3p (Fig. 3)17,18,20,24. Additionally, we compared differential expressed miRNAs to altered circulating miRNAs 
in maternal serum of pregnant women with fetal CHDs including TOF25,26. This revealed only two common TOF 
specific expressed miRNAs, namely miR-22 and miR-29c. They are down-regulated in heart tissue of our study 
while up-regulated in maternal serum in the study by Zhu et al.26.
target prediction of differentially expressed miRnAs. The set of 172 significantly differentially 
expressed miRNAs between TOF-rv and NH-rv was further selected for target prediction using MIRZA-G27 and 
TargetScanHuman28 and linking to 972 mRNAs, which are also significantly differentially expressed in the right 
ventricle of these patients and controls5,7. Note that the already published mRNA-seq data5,7 were generated from 
cardiac tissue of the same TOF and normal hearts. Following a stringent approach, we only selected negatively 
correlated miRNA-mRNA pairs (i.e., up-regulated miRNA and down-regulated mRNA, or vice versa), which 
corresponds to the main regulatory mechanism of miRNAs29. This prediction and filtering approach resulted 
in 344 pairs comprising 235 genes (protein-coding mRNAs) and only 11 miRNAs from 10 families (Fig. 4). The 
list of miRNA-gene pairs includes already validated pairs such as miR-1 & GJA1 (Gap Junction Protein Alpha 1), 
miR-140-5p & KLF9 (Kruppel Like Factor 9) and miR-1 & KCNJ2 (Potassium Voltage-Gated Channel Subfamily 
J Member 2), which are also included in public databases such as DIANA/miRTarBase30. GJA1 and KCNJ2, 
both targeted by miR-1, are two ion channel genes, which are known to play a major role in cardiac disease and 
development31.
Considering that mRNAs are typically targeted by many miRNAs and each miRNA targets multiple mRNAs, 
identified miRNA-gene pairs are part of co-regulation and interaction networks including competition between 
mRNAs and miRNAs. Thus, the target prediction workflow was extended to include a probabilistic model to 
identify miRNA-mRNA interaction signatures (ProMISe)32. The results are miRNA-gene pairs, which are most 
likely to occur given the whole expressed miRNA (n = 657) and mRNA (n = 11,997) background. Here, cases 
that are uniquely predicted in either TOF patients or normal heart controls are most interesting. This holds true 
for 19 pairs in the TOF patients (comprising 5 miRNAs and 18 genes) and 10 pairs in the controls (comprising 3 
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Figure 3. Overlap of significantly differentially expressed miRNAs in the right ventricle of TOF patients versus 
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miRNAs and 10 genes) (Fig. 4). The final 18 target genes in the TOF patients are significantly enriched for several 
cardiac-related Gene Ontology (GO) terms and pathways (Fig. 4).
novel miRnAs in the human heart. Approximately 8–9% of the mapped small RNA-seq reads could 
not be assigned to known miRNAs, other small non-coding RNAs, mRNAs or genomic repeats (Fig. 1A). 
Thus, we searched for novel miRNAs over all heart samples using a fold- and scoring-based approach33, which 
revealed three novel miRNA candidates. Moreover, all three miRNAs are significantly differentially expressed 
in the right ventricle of TOF patients compared to normal heart controls (Fig. 5 and Supplementary Figs. S4–
7). Most interestingly, the target prediction for the novel miRNA candidate located on chromosome 6 and in 
an intron of GLP1R (Glucagon-Like Peptide 1 Receptor) (Fig. 5A; Supplementary Fig. S5) revealed 15 target 
genes (Supplementary Table S2), which are enriched for several cardiac-related significantly enriched GO terms 
(e.g., cardiovascular system development) and pathways (e.g., cardiac hypertrophic response, hypertrophic 
and dilated cardiomyopathy, miRNAs in cardiomyocyte hypertrophy). Moreover, the interaction-like graph of 
processes and associated genes filtered for cardiac and developmental related GO terms shows that the target 
genes belong to the anatomical structure development and developmental growth (Fig. 5B). The target genes 
(in total 10; Supplementary Table S2) of the novel miRNA candidate located on chromosome 16 and overlap-
ping the long intergenic non-protein coding RNA 922 (LINC00922) (Supplementary Figs. S4A and S6) are 
significantly enriched for pathways such as ‘assembly of collagen fibrils and other multimeric structures’ and 
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‘collagen formation’. Significantly enriched GO terms for this miRNA are ‘sarcoplasm’ and ‘contractile fiber part’ 
among others. For the novel miRNA candidate located on chromosome 1 and in an intron of NKAIN1 (Na+/
K+ Transporting ATPase Interacting 1) (Supplementary Figs. S4B and S7), no significantly enriched GO terms 
and only ‘translation factors’ for the pathways were found based on the 31 target genes (Supplementary Table S2).
Discussion
Post-translational regulation of gene expression by non-coding RNAs plays an important role in multiple cel-
lular pathways and diseases. Here, genome-wide small RNA sequencing of cardiac biopsies from isolated TOF 
patients and healthy unaffected individuals was performed to investigate the role of miRNAs in the normal and 
malformed human heart. Deep sequencing revealed mostly up-regulated miRNAs in TOF compared to normal 
heart controls, which is in line with other heart failure studies34. Furthermore, our study design enabled us to find 
several miRNAs that are well-known for non-congenital heart diseases13,34,35 to be also altered in TOF patients.
Recently, sexual differences in miRNA expression of TOF hearts was shown, with miR-1 and miR-133 
accounting for the most variance between sexes22. In general, we do not observe significant sex-specific differ-
ences of miRNA expression profiles in our TOF cohort. For miR-1, the fold change of mean normalized read 
counts between male and female TOF hearts is 1.16, although there is a difference of approximately 800k reads 
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Figure 5. Predicted novel miRNA candidate located at chromosome 6 and in an intron of GLP1R. (A) The 
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TOF-rv samples is given on the right. (B) Interaction-like graph based on GOplot for processes and associated 
target genes of the novel miRNA filtered for significantly enriched cardiac- and development-related GO terms.
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(5.5 million normalized read counts for TOFs with 5.9 million reads for male TOFs and 5.1 million reads for 
female TOFs compared to 8.9 million read counts for NHs with 9.7 million reads for male NHs and 8.0 million 
reads for female hearts). For miR-133b, the fold change is 1.95 but there is only a difference of 471 reads in total 
(741 normalized read counts for TOFs with 966 reads for male TOFs and 495 reads for female TOFs compared 
to 2,107 read counts for NHs with 2,427 reads for male NHs and 1,787 reads for female hearts). However, both 
miRNAs are significantly down-regulated in TOF versus normal heart, which also holds true for a gender-specific 
analysis. In comparison to the normal heart, which is the subject of this study, sex-specific differences of miRNA 
expression profiles can be ignored as a balanced number of male and female TOF hearts (11 male and 10 female 
TOFs) and normal hearts (2 male and 2 female NHs) is compared.
Among the significantly altered miRNAs in TOF hearts are the down-regulated miR-1 & miR-133b (both 
associated with cardiac hypertrophy)31 and miR-29a (involved in the control of cardiac fibrosis)31 as well as the 
up-regulated miR-206 (involved in cardiac and skeletal muscle development)36. Interestingly, these miRNAs were 
not found to be altered in the already existing array- or sequencing-based studies based on right ventricular tissue 
of TOF patients17,18,20,24. This is surprising and might be explained by technical aspects such as platform (array 
versus sequencing), normalization strategy and read count statistic. In particular, the last two aspects are impor-
tant for highly expressed miRNAs such as miR-1 with more than one million reads for each sample. In general, 
the overlap with other TOF studies, which are already very heterogeneous in respect to their altered miRNAs, is 
limited with 25%, and only miR-222-3p overlaps all studies (Fig. 3). The miRNA-221/222 family may target sev-
eral genes involved in TGF-β signaling and recently it was shown that heart failure-associated down-regulation of 
this miRNA family enables profibrotic signaling in the pressure-overloaded heart37. Our TOF patients have been 
selected at a non-failing heart stage that is in line with a 3-fold up-regulation of miR-222-3p. Among technical 
aspects, the low overlap of the different studies could also be explained by gender, age, sample size and ethnic 
backgrounds14. More importantly, it reflects the complexity of the disease. The four abnormalities in TOF can all 
exhibit variable levels of severity and as a result, no two TOF cases are the same. We assigned subgroups of TOF 
cases based on their phenotypic features. Linear modeling techniques revealed influences of these subgroups on 
specific gene expression alterations38. Thus, we analyzed a homogenous group of TOF patients and normal heart 
controls in terms of their clinical parameters and features (Supplementary Fig. S1).
MiRNAs have also been described to be differently expressed and to regulate different cell types and pathways 
during cardiac aging39,40. In particular, the cardiac miR-21 is up-regulated with age in mice, and overexpression of 
Argonaut proteins synergistically induced miR-21. In general, major changes occurred later in life, from middle- 
to old-aged mice, and half of the candidate miRNAs were clustered39,40. A miRNA analysis on human skeletal 
muscle biopsies of young (~31 y) and older adults (~73 y) also revealed age-related differences (e.g., let-7 family 
members), and dysregulated miRNAs are related to genes associated with cell cycle, inflammation and stress41. 
For ethical reasons, it is highly difficult to have high quality cardiac samples of young children. This is further 
reflected by the limited availability of normal cardiac datasets from young children in general. The only solution 
to overcome this bottleneck is a conservative analysis and consideration of different aspects. In our study, we 
compared infant TOF hearts (0–3 y) to young/mid-age adult normal hearts. Our dysregulated miRNAs are not 
clustered (Fig. 2B). Moreover, we did not compare infant hearts to old adult hearts, where one could expect an 
increase of age-related pathways involved in for example cell cycle, inflammation or oxidative stress. Nevertheless, 
among possible age-related differentially expressed miRNAs (i.e., 5 out of 172) are miR-21 and let-7a. As men-
tioned above, miR-21 is up-regulated with age39,40 and a higher let-7 expression was described as a possible indi-
cator of impaired cell cycle function possibly contributing to reduced muscle cell renewal and regeneration in 
older human muscle41. However, it cannot be clearly determined whether differential expression of these miRNAs 
between TOF and normal heart is age- or disease-related. We strongly believe that our results build a good and 
solid basis for follow-up studies in humans and animals as well as cell culture models, which have to verify the 
causative impact of these dysregulated miRNAs.
To further reduce the list of significantly expressed miRNAs and to find candidates with impact on gene 
expression in TOF, target prediction incorporating significantly expressed mRNAs of the same patient and con-
trol cohort was performed. Combining miRNA and mRNA expression has been shown to be efficient to identify 
the top candidates out of a huge number of putative targets for each miRNA42. In addition, only negative corre-
lated miRNA-mRNA pairs were considered in this study as candidates, although miRNA-mRNA pairs can also 
be positively correlated und functional relevant43. Indeed, the proportion of positively and negatively correlated 
miRNA-mRNA pairs is equally distributed. However, the 344 negative correlated pairs were further reduced con-
sidering probabilistic miRNA–mRNA interaction signatures. Out of hundreds of expressed miRNAs and thou-
sands of expressed mRNAs in the TOF patients or normal heart controls, only 5 miRNAs and 18 genes negatively 
correlated in 19 pairs might have a significant probability to be disease-relevant in the TOF patients. Among 
them are for example miR-1 with the main K+ channel subunit responsible for setting and maintaining the car-
diac resting membrane potential (KCNJ2), miR-133b with a component of connective tissue microfibrils (FBN2; 
Fibrillin 2) or a sodium-dependent glutamine transporter (SLC38A3; Solute Carrier Family 38 Member 3), and 
miR-133b or miR-140-5p with the slow skeletal inhibitory subunit of the troponin complex (TNNI1 (Troponin 
I1, Slow Skeletal Type). Of note, we showed that the sarcomeric gene TNNI1 is also affected by DNA methylation 
changes co-localized with novel, differential splicing events in these TOF patients5.
The overlap of differentially expressed miRNA and mRNA expression profiles could dramatically reduce the 
huge number of putative mRNA targets potentially disease-relevant genes. However, translational repression and 
target mRNA degradation by miRNAs can only be one small aspect to fully understanding a complex phenotype 
like TOF. MiRNAs are part of larger co-regulation and interaction networks, which are influenced by multiple 
factors such as genomic variations, DNA methylation, other non-coding RNAs such as piwi-interacting RNAs or 
even alternative splicing events as in the case of TNNI1. This is also reflected by miRNA extension to a multilevel 
interaction network in TOF (Fig. 6)5. The network comprises mutated CHD genes and significantly differentially 
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expressed and methylated genes or miRNAs (based on the 344 miRNA-mRNA pairs) in the TOF patients. In 
summary, genome-wide miRNA and mRNA expression profiles of TOF patients and normal heart controls were 
investigated. We found several known and few novel altered miRNAs with respectively altered target genes in the 
right ventricle of TOF patients. Our data suggest disease-relevant miRNA-mRNA pairs that are open to further 
investigations in heart tissue as well as circulating in the blood.
Methods
ethics statement and samples. Studies of patients were performed according to the institutional 
guidelines of the German Heart Institute in Berlin, with approval of the ethics committee of the Charité - 
Universitätsmedizin Berlin and written informed consent of patients and/or parents, kin, caretakers, or guardians 
on behalf of the minors involved in our study. The study conforms to the principles outlined in the Declaration 
of Helsinki. The homogeneous cohort of isolated TOF cases (i.e., without any additional cardiovascular or other 
abnormalities) was selected based on our previous evaluations38,44. Moreover, the number of samples derived from 
male and female individuals is almost equally distributed for both TOF patients and controls (Supplementary 
Fig. S1; 2 female and 2 male normal hearts (left and right ventricular samples each from the same heart) as well 
as 10 female and 12 male TOF samples). Myocardial biopsies were taken during the first corrective surgery after 
short-term cardioplegia. Samples were collected in collaboration with the German Heart Institute in Berlin and 
directly snap-frozen in liquid nitrogen after excision and stored at −80 °C. Tissue from normal human hearts 
was obtained from unmatched organ donors without cardiac disease, where the hearts could not be transplanted 
because of organizational difficulties.
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network is based on the study by Grunert et al.5. The known mutated genes in CHD patients comprise a high 
number of transcriptional regulators (transcription factors and histone modification), while the connected 
genes with differential expression and methylation and/or targeted by altered miRNAs in the right ventricular 
tissue of TOF patients compared to normal heart controls consist mainly of downstream targets and signaling 
molecules. DMR indicates differentially methylated region; CHD, congenital heart disease.
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Small RNA sequencing, read mapping, annotation and quantification. The total RNA was iso-
lated and prepared for small RNA sequencing according to manufacturer’s protocol (Illumina 11251913 Rev. A; 
“Preparing Samples for Analysis of Small RNA”). Sequencing libraries were generated and purified DNA was used 
directly for sequencing. 36 bp single-end read sequencing was performed using the Illumina’s Genome Analyzer. 
The sequencing and probability output files were converted to FASTQ format using MAQ45. The quality of the 
sequencing data was checked using FASTQC (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). All 
samples passed sequence quality.
After initial quality check, the reads were mapped to the human reference genome (hg19) using MicroRazerS46. 
The parameters were set as follows: -m 20 (maximum number of best matches), -pa (purge ambiguous reads hav-
ing more than 20 equally-best hits) and -sL 18 (seed length for miRNA of length 19–25 nt). In addition, reads 
can have at most one error in the seed sequence to be robust towards possible sequencing errors and sequence 
variations. As MicroRazerS is prefix-based, meaning that the read mapper searches for the longest contiguous 
match starting at the first read base, no adapter trimming is required. Moreover, this mapping process is robust to 
possible sequencing errors, which especially occur at the 3′ end of reads46.
Mapped reads are annotated based on their overlap to known genomic annotations including precur-
sor and mature miRNAs, transfer RNAs (tRNA), C/D box & H/ACA small nucleolar RNAs (snoRNAs), cajal 
body-specific RNAs (scaRNAs), ribosomal RNAs (rRNAs), small cytoplasmic RNAs (scRNAs), small nuclear 
RNAs (snRNAs), miscellaneous other RNAs (miscRNAs), mitochondrial tRNAs (Mt-tRNAs), piwi-interacting 
RNAs (piRNAs), mRNAs and repeats. Annotations are obtained from the miRBase v20 (GRCh37) and UCSC 
database (tRNA, rnaGene, wgrna, knownGene and rmsk tracks; GRCh36/37). If a read overlapped to known 
mature/precursor miRNAs it was assumed that the read was a sequencing product of this miRNA and the read 
was added to its read count. All other small RNA classes were annotated in the same manner and ordered as 
mentioned above. Reads which could not be overlapped with any known annotations were declared as unknown 
sequences.
Differential expression analysis. To perform differential expression analysis, the miRNA read counts 
were normalized using the TCC method, which incorporates an overabundance of some heart-related miR-
NAs47. After removing outliers (TOF-09 and NH-03) based on multi-dimensional scaling, a negative binomial 
(gamma-Poisson) model was applied to miRNAs with a minimal tag count of more than 50 over all analyzed sam-
ples. An exact test was conducted to test differential expression appropriate for the negative binomially distrib-
uted miRNA read counts48. The observed p-values from gamma-Poisson tests of TCC normalized miRNA read 
counts follow a normal distribution (Supplementary Fig. S8A) and were further adjusted using the Benjamini and 
Hochberg (BH) correction method with a false discovery rate (FDR) smaller than 5%. Significantly differentially 
expressed miRNAs have a fold change above 1.5 (Supplementary Fig. S8B).
target prediction. To predict miRNA targets, the tools MIRZA-G27 and TargetScanHuman28 were used. 
Already pre-computed lists of targets genes for all human miRNAs were used for both tools and filtered for the 
set of significantly differentially expressed miRNAs (n = 172) and mRNAs (n = 972) in right ventricular tissue of 
TOF patients and normal heart controls. Note that the mRNA-seq data from the same TOF and normal hearts 
were already published by us and the data analysis including differential expression are described elsewhere5,7. As 
MIRZA-G combines all miRNA-mRNA pairs in one single pair, the same approach was applied to all TargetScan 
pairs. TargetScanHuman was adapted to report all miRNAs belonging to a miRNA family. All transcript scores 
for one gene were combined to one gene score. The score was taken from best score over all transcripts. The 
scores of MIRZA-G ranged between 0 and 3.6 and for TargetScan between −3 and −0.02. No additional thresh-
olds were applied to the scores. The predicted miRNA-mRNA pairs were further filtered applying a probabilistic 
miRNA-mRNA interaction signature (ProMISE) approach32 using all expressed miRNAs (n = 657 with TCC > 1 
in at least one individual) and mRNA (n = 11,977 with Reads Per Kilobase Million (RPKM) > 1 in at least one 
individual) in TOFs and/or controls. Only pairs with a ProMISE score > 0.004 were used (~90% quantile in 
NH-rv and ~87% quantile in TOF-rv). Over-representation analysis for GO terms and biological pathways based 
on genes identified in miRNA-mRNA pairs after ProMISE filtering was performed using ClueGO (adjusted 
p-value ≤ 0.05 using hypergeometric test with correction for multiple testing using Benjamini-Hochberg 
method)49.
novel miRnA prediction. The fold- and scoring-based approach of the miRDeep package was used 
to identify novel miRNAs33. Briefly, all read sequences with a mapped read length of less or equal than 25 nt 
(longer sequences are unlikely to represent mature miRNA sequences) as well as a sequence count of more than 
25 (removing noise) which are not annotated to known miRNAs or other small non-coding RNAs were used 
for novel miRNA prediction. Within the miRDeep approach, each potential miRNA precursor sequence was 
assessed after folding into a hairpin structure using the RNA folding algorithm from the ViennaRNA pack-
age50. Furthermore, miRDeep searches for potential cleavage sites of Drosha and Dicer, and uses phylogenetic 
conservation and a filtering of other known small non-coding RNA species to improve the predictions. The 
stability of potential precursors sequences is tested using Randfold v2.051. In summary, each potential miRNA 
precursor sequence was scored based on its read signature, secondary structure (e.g., multi-loops, minimum free 
energy, etc.), cleavage, conservation and overlap to known small non-coding RNAs. The novel miRNA candidates 
were further subjected to differential expression analysis along all known miRNAs (TCC normalized counts, 
negative binomial testing, multiple testing, adjusted p-value < 0.05). For each novel miRNA, target prediction 
was performed based on TargetScanHuman28 using differential expressed mRNAs in TOF-rv versus NH-rv 
and filtering by an aggregated PCT score > 0.8, a context++ score ≤0.4 and a percentile >8552. For the sets of 
target genes, on over-representation analysis for GO terms and pathways was performed using ClueGO49 and 
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ConsensusPathDB53 (adjusted p-value ≤ 0.05 using hypergeometric test with correction for multiple testing using 
Benjamini-Hochberg method).
Data availability
Small RNA-seq data has been submitted to the Gene Expression Omnibus (GEO) repository at NCBI (accession 
number GSE36759). RNA-seq data for TOF-rv and NH-rv samples are also available at the GEO repository 
(accession number GSE36761).
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